Published in Cochrane Database Syst Rev on April 16, 2008
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med (2012) 2.66
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer (2009) 1.09
Renal cell carcinoma: molecular biology and targeted therapy. Curr Opin Oncol (2014) 1.01
Multi-modal treatment for metastatic renal cancer: the role of surgery. World J Urol (2010) 1.01
Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Int J Cancer (2014) 1.00
Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha. Br J Cancer (2010) 0.90
Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy (2011) 0.89
Updates on novel therapies for metastatic renal cell carcinoma. Ther Adv Med Oncol (2010) 0.89
Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. Onco Targets Ther (2015) 0.88
The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy. Oncoimmunology (2015) 0.83
Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. Biologics (2010) 0.83
Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma. Br J Cancer (2012) 0.83
Wnt Signaling in Renal Cell Carcinoma. Cancers (Basel) (2016) 0.82
Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma. Cancer Immunol Immunother (2011) 0.81
Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. Clinicoecon Outcomes Res (2011) 0.80
Sunitinib for advanced renal cell cancer. Biologics (2008) 0.79
Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities. Immunotargets Ther (2013) 0.79
Cytoreductive surgery in the era of targeted molecular therapy. Transl Androl Urol (2015) 0.78
[Renal cell carcinoma]. Urologe A (2011) 0.78
Complete metastasectomy for renal cell carcinoma: Comparison of five solid organ sites. J Surg Oncol (2016) 0.78
ARHGAP24 inhibits cell cycle progression, induces apoptosis and suppresses invasion in renal cell carcinoma. Oncotarget (2016) 0.77
State-of-the-art treatment of metastatic renal cell carcinoma. Curr Oncol (2009) 0.75
Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center. Drug Des Devel Ther (2014) 0.75
Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis. Transl Oncol (2016) 0.75
Antitumor effect and biological pathways of a recombinant adeno-associated virus as a human renal cell carcinoma suppressor. Tumour Biol (2014) 0.75
Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer. Oncotarget (2016) 0.75
Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma. Mol Clin Oncol (2017) 0.75
Limited benefit of targeted molecular therapy for inferior vena cava thrombus associated with renal cell carcinoma. Int J Clin Oncol (2017) 0.75
Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial. Radiat Oncol (2017) 0.75
Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (2005) 3.88
Use of model plant hosts to identify Pseudomonas aeruginosa virulence factors. Proc Natl Acad Sci U S A (1997) 3.88
Screening for prostate cancer. Cochrane Database Syst Rev (2006) 3.46
A comparison of video modeling with in vivo modeling for teaching children with autism. J Autism Dev Disord (2000) 2.58
Emergency ultrasound-based algorithms for diagnosing blunt abdominal trauma. Cochrane Database Syst Rev (2005) 2.28
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer (2006) 2.23
Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev (2002) 2.07
Soluble tumor necrosis factor receptors correlate with parasitemia and disease severity in human malaria. J Infect Dis (1992) 1.98
Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer (1997) 1.85
Treatment decisions in palliative cancer care: patients' preferences for involvement and doctors' knowledge about it. Eur J Cancer (1997) 1.83
Cardiopulmonary manifestations of Henoch-Schönlein purpura. Am J Kidney Dis (2000) 1.61
The impact and recovery of asteroid 2008 TC(3). Nature (2009) 1.60
A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev (2008) 1.57
Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. Lancet Infect Dis (2001) 1.53
[Evidence-based medicine and anaesthesiology--six steps towards implementation into clinical practice]. Anasthesiol Intensivmed Notfallmed Schmerzther (2003) 1.37
A likelihood ratio approach to meta-analysis of diagnostic studies. J Med Screen (2003) 1.30
Systematic review and meta-analysis of emergency ultrasonography for blunt abdominal trauma. Br J Surg (2001) 1.20
[Emergency ultrasound for blunt abdominal trauma--meta-analysis update 2003]. Zentralbl Chir (2003) 1.15
Differential diagnosis of bronchiolitis obliterans with organizing pneumonia and usual interstitial pneumonia: clinical, functional, and radiologic findings. Radiology (1987) 1.15
A comparison of bronchiolitis obliterans with organizing pneumonia, usual interstitial pneumonia, and small airways disease. Am Rev Respir Dis (1987) 1.15
Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia. Blood (1989) 1.14
Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev (2006) 1.08
Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev (2000) 1.07
Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol (1994) 1.07
Physical activity, medical history, and risk of testicular cancer (Alberta and British Columbia, Canada). Cancer Causes Control (1995) 1.06
Practical aspects of quality-of-life measurement: design and feasibility study of the quality-of-life recorder and the standardized measurement of quality of life in an outpatient clinic. Cancer Treat Rev (1996) 1.05
Exponential analysis of the pressure-volume curve. Correlation with mean linear intercept and emphysema in human lungs. Am Rev Respir Dis (1988) 1.04
Incidence of endocrine disease among residents of New York areas of concern. Environ Health Perspect (2001) 1.01
Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol (1996) 0.98
Posttraumatic concerns: a patient-centered approach to outcome assessment after traumatic physical injury. Med Care (2001) 0.96
Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (2000) 0.96
Application of two-dimensional total correlation spectroscopy for structure determination of individual inositol phosphates in a mixture. Anal Biochem (1995) 0.96
Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. J Clin Oncol (1998) 0.95
Interventions for chronic abacterial prostatitis. Cochrane Database Syst Rev (2001) 0.95
High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia. J Clin Invest (1992) 0.93
Cloning, sequencing, and heterologous expression of the elmGHIJ genes involved in the biosynthesis of the polyketide antibiotic elloramycin from Streptomyces olivaceus Tü2353. J Nat Prod (2001) 0.93
Human interleukin-7 induces proliferation of neoplastic cells from chronic lymphocytic leukemia and acute leukemias. Blood (1991) 0.92
Polymorphism within the second intron of the IL-1 receptor antagonist gene in patients with hematopoietic malignancies. Cytokines Mol Ther (1996) 0.90
Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials. Cancer Treat Rev (2009) 0.89
A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer. Ann Oncol (2009) 0.89
Comparison between microwell and bead supports for the detection of human cytomegalovirus amplicons by sandwich hybridization. Anal Biochem (1997) 0.89
[Reversible germ cell toxicity following aggressive chemotherapy in patients with testicular tumors: results of a prospective study]. Klin Wochenschr (1989) 0.88
Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ) (1999) 0.88
Characterization of revertants of a Sindbis virus 6K gene mutant that affects proteolytic processing and virus assembly. Virus Res (1995) 0.88
Pleurisy and methotrexate treatment. Br Med J (1977) 0.88
Interleukin-6 stimulates the hypothalamus-pituitary-adrenocortical axis in man. J Clin Endocrinol Metab (1994) 0.87
Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha genes in chronic lymphocytic leukaemia. Br J Haematol (1997) 0.86
Epidemiology of high-grade prostatic intraepithelial neoplasia. Scand J Urol Nephrol Suppl (2000) 0.85
Stimulation of human NK-cell activity by cultured cells. I. Response of normals. Int J Cancer (1978) 0.85
Spontaneous interferon-alpha antibodies in a patient with pure red cell aplasia and recurrent cutaneous carcinomas. Ann Hematol (1991) 0.85
[Challenge of evidence-based medicine: sense and non-sense of diagnostic tests in gynecology]. Zentralbl Gynakol (2001) 0.84
Surgery versus radiotherapy for muscle invasive bladder cancer. Cochrane Database Syst Rev (2002) 0.84
A four base pair insertion polymorphism in the 3' untranslated region of the COL1A1 gene is highly informative for null-allele testing in patients with osteogenesis imperfecta type I. Matrix Biol (1998) 0.84
Autocrine and paracrine regulation of neoplastic cell growth in hairy cell leukemia. Leuk Lymphoma (1995) 0.83
Evidence for the involvement of host-derived OKT8-positive T cells in the rejection of T-depleted, HLA-identical bone marrow grafts. Transplantation (1987) 0.83
An episode of accelerated amino acid change in Drosophila esterase-6 associated with a change in physiological function. Genetica (2000) 0.82
[Detection of tumorantigens of hypernephroma (author's transl)]. Urol Int (1973) 0.82
[Methods of health economic evaluation for health services research]. Gesundheitswesen (2010) 0.81
[Spontaneous remission of sudden deafness]. HNO (2000) 0.81
Natural killer cell activity in preleukaemia. Lancet (1982) 0.81
p53 mutations in hairy cell leukemia. Leukemia (2000) 0.81
Interferon-alpha antibodies in autoimmune diseases. J Interferon Res (1989) 0.81
Comparison of German language versions of the QWB-SA and SF-36 evaluating outcomes for patients with prostate disease. Qual Life Res (2001) 0.81
Otoprotective effects of erythropoietin on Cdh23erl/erl mice. Neuroscience (2013) 0.81
The electrophoretic mobility test (EMT) and cancer diagnosis. Z Immunitatsforsch Immunobiol (1978) 0.80
Differential effect of GM-CSF and G-CSF in cyclic neutropenia. Lancet (1990) 0.80
Impaired natural killer cell function in hemophiliacs with or without continuous substitution. Blut (1984) 0.80
Antibodies to interferon-alpha: a novel type of autoantibody occurring after allogeneic bone marrow transplantation. Bone Marrow Transplant (1996) 0.79
Tumor necrosis factor-alpha, but not lymphotoxin, stimulates growth of tumor cells in hairy cell leukemia. Leukemia (1990) 0.78
[Lay assessment of health care services using therapy for rectal cancer as an example]. Zentralbl Chir (2008) 0.78
Surgical treatment of lung cancer: promise and problems of early diagnosis. Can J Surg (1986) 0.78
High-titre interferon-alpha antibodies in a patient with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant (1994) 0.78
Impaired T-cell and NK-cell function in patients with preleukemia. Blut (1982) 0.78
Bone densitometry and histomorphometry in patients with hairy cell leukemia. Leuk Lymphoma (1994) 0.78
Paraneoplastic demyelinating disorder in the brain of a patient with seminoma. J Comput Assist Tomogr (1998) 0.78
Physicians' decision-making in incompetent elderly patients: a comparative study between Austria, Germany (East, West), and Sweden. Int Psychogeriatr (1999) 0.78
Observations regarding hairy cell leukemia and chronic lymphocytic leukemia within the proposed new classification of lymphoid neoplasms. Blood (1995) 0.77
Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha genes in hairy cell leukaemia. Br J Haematol (1997) 0.77
Receptors for tumor necrosis factor on neoplastic B cells from chronic lymphocytic leukemia are expressed in vitro but not in vivo. Blood (1990) 0.76
A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia. Blut (1989) 0.76
Tumour necrosis factor and hairy cell leukaemia. Lancet (1988) 0.76
Drug delivery analysis of the Canadian multicenter trial in non-small-cell lung cancer. J Clin Oncol (1994) 0.76
Neurophysiological effects of recombinant interferon-gamma and -alpha in man. Clin Physiol Biochem (1989) 0.75
When should hairy cell leukaemia be treated? Lancet (1990) 0.75
[What is the benefit of mammography? -- mammography screening: careful consideration required]. Dtsch Med Wochenschr (2013) 0.75
Stimulation of human NK cell activity by cultured cells. II Ingestion of aspirin by blood donors suppresses induced NK activity. Clin Exp Immunol (1981) 0.75
Considerations on the pathogenesis of acute myeloid leukaemia in a splenectomized hairy cell leukaemia patient treated with interferon-alpha. Br J Haematol (1994) 0.75
The clinical evaluation of hairy cell leukemia. Blood (1992) 0.75
[Retinoids in oncology]. Dtsch Med Wochenschr (1993) 0.75
Filter spot-ELISA for the enumeration of interferon-alpha antibody-secreting cells. J Immunol Methods (1990) 0.75
Immunologically defined subclasses of the growth suppressor protein p53 detected with antibodies in sera from tumor patients. Int J Oncol (1993) 0.75
Variations in the susceptibility to lysis of NK target cells. Oncology (1984) 0.75
Sensitive antiproliferative neutralization assay for the detection of neutralizing IFN-alpha and IFN-beta antibodies. J Immunol Methods (1994) 0.75
[Advantages and problems of interdisciplinary tumor conferences]. Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir (1990) 0.75
[Comparative biochemical studies on transurethral and transvesical prostatectomy. II. Behavior of plasma hemoglobin and haptoglobin, protein and fat metabolism, phosphatases]. Bruns Beitr Klin Chir (1972) 0.75
Capillary leak syndrome associated with elevated IL-2 serum levels after allogeneic bone marrow transplantation. Ann Hematol (1994) 0.75
Pharmacokinetics and biological activity in subcutaneous long-term administration of recombinant interferon-gamma in cancer patients. Cancer Immunol Immunother (1991) 0.75
Recombinant interferon-alpha 2 antibodies in renal cell carcinoma. Delta-P Study Group. J Interferon Res (1994) 0.75